Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days

Annals of Oncology

Volumn 9, Issue 12, 1998, Pages 1315-1322

  Sessa, C ^a   Minoia, Claudio ^b   Ronchi, Anne ^b   Zucchetti, Massimo ^c   Bauer, J ^e,f   de Jong, Jeroen P J ^a   Pagani, Olivia ^a   Renard, J ^d   Weil, C ^d   D'Incalci MD, Maurizio ^c  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b IRCCS   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d BRISTOL MYERS SQUIBB   (United States)

^e Multidisciplinary Oncology Center   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Oral chemotherapy; Oral platinum analogue; Phase I

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; LOPERAMIDE; MITOMYCIN; NITROSOUREA DERIVATIVE; PARACETAMOL; SATRAPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG FORMULATION; DRUG RESISTANCE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT MESOTHELIOMA; MASS SPECTROMETRY; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; VOMITING;

EID: 0032423757     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008441416790     Document Type: Article

References (13)

1. Kelland LR, Abel G, Me Keage MJ et al. Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug. Cancer Res 1993; 53: 2581-6.
2. Mc Keage MJ, Kelland LR, Boxall FE et al. Schedule dependency of orally administered Bis-acetato-dichlorocyclohexylamine-platinum (IV) (JM216) in vivo. Cancer Res 1994; 54: 4118-22.
3. Me Keage MJ, Morgan SE, Boxall FE et al. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer 1993; 67: 996-1000.
4. Me Keage MJ, Boxall FE, Jones M, Harrap KR. Lack of neurotoxicity of oral bis acetato amine dichloro cyclohexylamine platinum (IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 1994; 54: 629-31.
5. Me Keage MJ, Mistry P, Ward J et al. A phase I and pharmacology study of an oral platinum complex JM216: Dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 1995; 36: 451-8.
6. Me Keage MJ, Raynaud F, Ward J et al. Phase I and pharmacokinetic study of an oral platinum complex given daily for five days in patients with cancer. J Clin Oncol 1997; 15: 2691-700.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
8. Casetta B, Roncadin M, Montanari G, Furlanut M. Determination of platinum in biological fluids by ICP-mass spectrometry. Atom Spectrom 1991; 12: 81-6.
9. Sacchi-Landriani G, Guardabasso V, Rocchetti M. NL-FIT: A microcomputer program for non-linear fitting. Comput Programs Biomed 1983; 16: 35-42.
10. Raynaud FI, Mistry P, Donaghue A et al. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 1996; 38: 155-62.
11. Judson I, Cerny T, Epelbaum R et al. Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Ann Oncol 1997; 8: 604-6.
12. Rose WC. Combination chemotherapy involving orally administered etoposide and JM216 in murine tumor models. Cancer Chemother Pharmacol 1997; 40: 51-6.
13. Ratain MJ, De Mario MD, Vogelzang NJ et al. A Phase I study of oral uracil/ftorafur (UFT) plus leucovorin (LV) and oral JM216 each given over 14 days every 28 days. Proc Am Soc Clin Oncol 1998; 17: Abstr 774.